Figure 10.

Effect of methionine on osteoclastogenesis in vitro. (A) Changes in the level of TRAP5b in blood borne-derived osteoclast cultures grown (developing osteoclasts) in osteoclastogenic media (M-CSF: 25 μg·L⁻¹, days 1–11 and TNFSF11: 20 μg·L⁻¹, days 6–20) in the presence and absence of methionine (10, 50 and 100 μg·mL⁻¹). (B, panels a–e) Photographs showing changes in developing osteoclasts grown in osteoclastogenic media (M-CSF 25 μg·L⁻¹, days 1–11 and TNFSF11 20 μg·L⁻¹, days 6–20), in the presence and absence of methionine. Red arrow indicates developing osteoclast. Green arrows show absence of osteoclast morphology in methionine (10 and 50 μg·mL⁻¹) treated cell culture. (C) TRAP5b level in matured osteoclast cultures (developed osteoclasts) in the presence and absence of methionine. Osteoclasts were grown in (M-CSF, 25 μg L⁻¹ for days 1–11 and TNFSF11, 20 μg L⁻¹ for days 6–20) for 25 days and then incubated with methionine (50 μg·mL⁻¹) for 5 days. Values are mean ± SEM of four independent experiments. *P < 0.05 compared with basal. **P < 0.05 compared with M-CSF/TNFSF11 control. BMC, blood mononuclear cell.